Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Pain Res Manag ; 2021: 8810178, 2021.
Article in English | MEDLINE | ID: mdl-33532013

ABSTRACT

Chronic neck pain (CNP) is a major concern for pain therapists. Many drugs including antidepressants such as amitriptyline have been used in the management of CNP. This study compared the efficacy and safety of 2 different doses of amitriptyline (5 mg and 10 mg at bedtime) in patients with CNP. A total of 80 patients of both sexes with idiopathic CNP, ranging in age from 18 to 75 years, were divided into 2 groups that received 5 or 10 mg oral amitriptyline at bedtime for 120 days. The primary outcome measure was neck pain disability index (NPDI). Neck pain intensity, Athens Insomnia Scale score, Hospital Anxiety and Depression Scale (HADS), side effects of the drug, and patient satisfaction were secondary outcome measures. NPDI decreased by 71.9% ± 13.4% in the 10 mg group compared to 47.3% ± 17.3% in the 5 mg group, representing a statistically significant difference (95% confidence interval: 27.3-12.6). Additionally, the 10 mg group showed greater mean reductions in pain score and HADS scores (both the anxiety and depression subscales), as well as improvement in sleep disturbance compared to the 5 mg group. A higher dose (10 mg) of amitriptyline at bedtime significantly reduced neck pain intensity, sleep disturbance, and anxiety and depression compared to a lower dose (5 mg) in patients with idiopathic and nontraumatic CNP after 120 days of treatment, with no significant difference between groups in the rate of side effects.


Subject(s)
Adrenergic Uptake Inhibitors/therapeutic use , Amitriptyline/therapeutic use , Chronic Pain/drug therapy , Neck Pain/drug therapy , Adolescent , Adrenergic Uptake Inhibitors/pharmacology , Adult , Aged , Amitriptyline/pharmacology , Double-Blind Method , Female , Humans , Male , Middle Aged , Treatment Outcome , Young Adult
2.
BMC Anesthesiol ; 18(1): 179, 2018 11 30.
Article in English | MEDLINE | ID: mdl-30501612

ABSTRACT

BACKGROUND: Regional anesthesia could affect the homeostatic system functions resulting frequently in perioperative hypothermia and consequently shivering. The objective of this trial was to evaluate the efficacy of dexmedetomidine and ondansetron to reduce the incidence and severity of shivering after intrathecal blocks. METHODS: This randomized placebo-controlled trial included 120 patients allocated equally in three groups. All patients were anesthetized by standard intrathecal blocks for surgical procedure at lower half of the body and received one of the study drugs intravenously (IV) according to the group assignments. Group S patients (placebo) were administered saline, Group O (ondansetron) were given 8 mg ondansetron, and Group D (dexmedetomidine) were given 1 µg/kg of dexmedetomidine. Shivering incidence and scores, sedation scores, core body temperature, hemodynamic variables, and incidence of complications (nausea, vomiting, hypotension, bradycardia, over-sedation, and desaturation) were recorded. RESULTS: The incidence and 95% confidence interval (95% CI) of shivering in group S 57.5% (42.18-72.82%) was significantly higher than that of both group O 17.5% (5.73-29.27%), P < 0.001 and group D 27.5% (13.66-41.34%), P = 0.012. However, the difference in the incidence of shivering between group O and group D was comparable, P = 0.425. The sedation scores were significantly higher in group D than those of both group S and group O, P < 0.001. Sedation scores between group S and group O were comparable, P = 0.19. Incidences of adverse effects were comparable between the three groups. CONCLUSION: Prophylactic administrations of dexmedetomidine or ondansetron efficiently decrease the incidence and severity of shivering after spinal anesthesia as compared to placebo without significant difference between their efficacies when compared to each other. TRIAL REGISTRATION: Pan African Clinical Trial Registry (PACTR) under trial number (PACTR201710002706318). 18-10-2017. 'retrospectively registered'.


Subject(s)
Anesthesia, Spinal/adverse effects , Dexmedetomidine/administration & dosage , Hypnotics and Sedatives/administration & dosage , Ondansetron/administration & dosage , Postoperative Complications/prevention & control , Shivering/drug effects , Adult , Anesthesia, Spinal/trends , Antiemetics/administration & dosage , Blood Pressure/drug effects , Blood Pressure/physiology , Female , Heart Rate/drug effects , Heart Rate/physiology , Humans , Male , Pilot Projects , Postoperative Complications/diagnosis , Postoperative Complications/etiology , Prospective Studies , Shivering/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...